keyword
MENU ▼
Read by QxMD icon Read
search

Neoadjuvant chemotherapy of lung cancer

keyword
https://www.readbyqxmd.com/read/28426673/lymph-node-volume-predicts-survival-but-not-nodal-clearance-in-stage-iiia-iiib-nsclc
#1
Vishesh Agrawal, Thibaud P Coroller, Ying Hou, Stephanie W Lee, John L Romano, Elizabeth H Baldini, Aileen B Chen, David Kozono, Scott J Swanson, Jon O Wee, Hugo J W L Aerts, Raymond H Mak
BACKGROUND: Locally advanced non-small cell lung cancer (LA-NSCLC) patients have poorer survival and local control with mediastinal node (N2) tumor involvement at resection. Earlier assessment of nodal burden could inform clinical decision-making prior to surgery. This study evaluated the association between clinical outcomes and lymph node volume before and after neoadjuvant therapy. MATERIALS AND METHODS: CT imaging of patients with operable LA-NSCLC treated with chemoradiation and surgical resection was assessed...
2017: PloS One
https://www.readbyqxmd.com/read/28416124/assessment-of-the-external-validity-of-the-national-comprehensive-cancer-network-and-european-society-for-medical-oncology-guidelines-for-non-small-cell-lung-cancer-in-a-population-of-patients-aged-80-years-and-older
#2
REVIEW
Nicolò Matteo Luca Battisti, Marina Sehovic, Martine Extermann
Non-small-cell lung cancer (NSCLC) is a disease of the elderly, who are under-represented in clinical trials. This challenges the external validity of the evidence base for its management and of current guidelines, that we evaluated in a population of older patients. We retrieved randomized clinical trials (RCTs) supporting the guidelines and identified 18 relevant topics. We matched a cohort of NSCLC patients aged older than 80 years from the Moffitt Cancer Center database with the studies' eligibility criteria to check their qualification for at least 2 studies...
March 21, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28410809/a-randomized-phase-ii-trial-of-concurrent-chemoradiation-with-two-doses-of-radiotherapy-60gy-and-66gy-concomitant-with-a-fixed-dose-of-oral-vinorelbine-in-locally-advanced-nsclc
#3
Olfred Hansen, Marianne M Knap, Azza Khalil, Christa H Nyhus, Tine McCulloch, Bente Holm, Carsten Brink, Lone Hoffmann, Tine Schytte
INTRODUCTION: In order to test the best performing radiation dose with a convenient chemotherapy schedule of an oral formulation of radio-sensitizing vinorelbine in inoperable locally advanced non-small cell lung cancer (NSCLC), we performed a randomized phase II trial based on a "pick the winner" design. METHODS: After 2 cycles of neoadjuvant chemotherapy, 117 patients with NSCLC stage IIB-IIIB in performance status 0-1 were randomized to radiotherapy 60Gy/30 fractions or 66Gy/33 fractions concurrent with a fixed dose of oral vinorelbine 50mg administered 3 times weekly...
April 11, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28399858/ku80-correlates-with-neoadjuvant-chemotherapy-resistance-in-human-lung-adenocarcinoma-but-reduces-cisplatin-pemetrexed-induced-apoptosis-in-a549-cells
#4
Bin Shang, Yang Jia, Gang Chen, Zhou Wang
BACKGROUND: Ku80 is a DNA repair protein which involves in cell apoptosis and chemoresistance. However, it is unclear whether Ku80 correlates with the efficiency of neoadjuvant chemotherapy in human lung adenocarcinoma, and modulates cisplatin/pemetrexed-induced lung cancer cell apoptosis in vitro. METHODS: We recruited 110 patients with stage IIIA lung adenocarcinoma, who received 2 cycles of neoadjuvant chemotherapy, and their lungs were reevaluated by CT scan...
April 11, 2017: Respiratory Research
https://www.readbyqxmd.com/read/28387221/a-3q-gene-signature-associated-with-triple-negative-breast-cancer-organ-specific-metastasis-and-response-to-neoadjuvant-chemotherapy
#5
Jun Qian, Heidi Chen, Xiangming Ji, Rosana Eisenberg, A Bapsi Chakravarthy, Ingrid A Mayer, Pierre P Massion
Triple negative breast cancers (TNBC) are aggressive tumors, with high rates of metastatic spread and targeted therapies are critically needed. We aimed to assess the prognostic and predictive value of a 3q 19-gene signature identified previously from lung cancer in a collection of 4,801 breast tumor gene expression data. The 3q gene signature had a strong association with features of aggressiveness such as high grade, hormone receptor negativity, presence of a basal-like or TNBC phenotype and reduced distant metastasis free survival...
April 7, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28343156/ectopic-acth-producing-large-cell-neuroendocrine-pancoast-tumour-presenting-as-horner-syndrome
#6
Rajanshu Verma, Alexandra Lambert, Harold H Katz, Scott J Benson
We present an interesting case where a patient is presented with a droopy left eyelid (as part of Horner syndrome) and Cushingoid features which were a result of a Pancoast tumour (apical lung tumour in superior pulmonary sulcus) involving the left lung. This tumour was secreting ectopic adrenocorticotropic hormone (ACTH), a paraneoplastic endocrine phenomenon, which resulted in Cushing syndrome symptomatology. Though most ectopic ACTH-producing lung cancers are either small cell or carcinoid tumours, this was in fact a large cell neuroendocrine cancer (LCNEC)...
March 24, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28327923/heart-dose-exposure-as-prognostic-marker-after-radiotherapy-for-resectable-stage-iiia-b-non-small-cell-lung-cancer-secondary-analysis-of-a-randomised-trial
#7
M Guberina, W Eberhardt, M Stuschke, T Gauler, F Heinzelmann, D Cheufou, M Kimmich, G Friedel, H Schmidberger, K Darwiche, V Jendrossek, M Schuler, G Stamatis, C Pöttgen
BACKGROUND: Heart exposure to ionizing irradiation can cause ischemic heart disease. The partial heart volume receiving ≥5 Gy (heartV5) was supposed to be an independent prognostic factor for survival after radiochemotherapy for locally advanced non-small cell lung cancer (NSCLC). But validation of the latter hypothesis is needed under the concurrent risks of lung cancer patients. PATIENTS AND METHODS: The ESPATUE phase III trial recruited patients with potentially operable IIIA(N2)/selected IIIB NSCLC between 01/2004 and 01/2013...
February 21, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28256629/personalized-chemotherapy-selection-for-breast-cancer-using-gene-expression-profiles
#8
Kaixian Yu, Qing-Xiang Amy Sang, Pei-Yau Lung, Winston Tan, Ty Lively, Cedric Sheffield, Mayassa J Bou-Dargham, Jun S Liu, Jinfeng Zhang
Choosing the optimal chemotherapy regimen is still an unmet medical need for breast cancer patients. In this study, we reanalyzed data from seven independent data sets with totally 1079 breast cancer patients. The patients were treated with three different types of commonly used neoadjuvant chemotherapies: anthracycline alone, anthracycline plus paclitaxel, and anthracycline plus docetaxel. We developed random forest models with variable selection using both genetic and clinical variables to predict the response of a patient using pCR (pathological complete response) as the measure of response...
March 3, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28228221/-efficacy-and-potential-application-of-neoadjuvant-chemotherapy-in-patients-with-iiia-stage-non-small-cell-lung-cancer
#9
Cuiping Tang, Si Qin, Wanchun Wu, Yang Wu, Tao Zhang
BACKGROUND: The therapeutic effect and side effect of neoadjuvant chemotherapy were still disputing issues when applied to resectable IIIa stage non-small cell lung cancer (NSCLC) patients. The retrospective analysis was aimed to investigate the short-term efficacy and postoperative complications in resectable IIIa NSCLC patients treated with neoadjuvant chemotherapy. METHODS: According to inclusion criteria and exclusion criteria, 370 patients with clinical diagnosis of IIIa NSCLC were selected from our hospital between January 2011 and October 2013 were retrospectively analyzed...
February 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28228219/-analysis-of-efficacy-of-surgical-treatment-for-iiia-small-cell-lung-cancer
#10
Xuejun Dou, Zhiyuan Wang, Liang Wang, Weiqiang Lu, Yunlei Ma, Shaofa Xu
BACKGROUND: Small cell lung cancer (SCLC) accounts for nearly 15% of all cases of cancer. As a type of highly invasive tumors, SCLC has high degree of malignancy, early and extensive metastasis, and is sensitive to chemotherapy and radiotherapy. The early treatment response rate of SCLC is high but it can also relapse rapidly without any treatment. Its median survival time is merely four to six months. Although many studies on SCLC have been conducted in recent years, its clinical treatment strategies have remained unchanged...
February 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28215851/a-novel-neoadjuvant-therapy-for-operable-locally-invasive-non-small-cell-lung-cancer-phase-i-study-of-neoadjuvant-stereotactic-body-radiotherapy-linnearre-i-nct02433574
#11
Nhu-Tram A Nguyen, Naghmeh Isfahanian, Gregory Pond, Wael Hanna, Jean-Claude Cutz, James Wright, Anand Swaminath, Yaron Shargall, Tom Chow, Marcin Wierzbicki, Gordon Okawara, Kimmen Quan, Christian Finley, Rosalyn Juergens, Theodoros Tsakiridis
BACKGROUND: Despite improved staging and surgical techniques, the rate of incomplete resection (R1) of non-small-cell lung cancer (NSCLC) has not significantly decreased. Patients with R1 resection have worse survival compared with those with complete resection (R0). Stereotactic body radiotherapy (SBRT) is a rapid and convenient radiotherapy treatment that delivers high-dose radiotherapy to tumors with high precision while sparing normal organs. Although its efficacy in treating small lung tumors is documented, its use as neoadjuvant therapy for locally advanced (LA) NSCLC has not been examined...
January 31, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28214087/targeting-the-pd-1-pd-l1-axis-in-non-small-cell-lung-cancer
#12
REVIEW
Rajiv Kumar, Dearbhaile Collins, Saoirse Dolly, Fiona McDonald, Mary E R O'Brien, Timothy A Yap
The last decade has witnessed rapid advances in the discovery and development of immune checkpoint inhibitors in cancer medicine, particularly drugs targeting programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC). The proven antitumor efficacy coupled with low rates of drug-related toxicities observed, albeit idiosyncratic, with these novel immunotherapeutics have led to the registration of multiple PD-1 and PD-L1 inhibitors, such as nivolumab, pembrolizumab, and atezolizumab, in second-line advanced NSCLC, whereas durvalumab and avelumab are in late-phase clinical testing...
December 23, 2016: Current Problems in Cancer
https://www.readbyqxmd.com/read/28181384/resection-of-synchronous-liver-metastases-between-radiotherapy-and-definitive-surgery-for-locally-advanced-rectal-cancer-short-term-surgical-outcomes-overall-and-recurrence-free-survivals
#13
K J Labori, M G Guren, K W Brudvik, B I Røsok, A Waage, A Nesbakken, S Larsen, S Dueland, B Edwin, B A Bjørnbeth
AIM: There is debate as to the correct treatment algorithm sequence for patients with locally advanced rectal cancer with liver metastases. The aim of the study was to assess safety, resectability, and survival after a modified "liver-first" approach. METHOD: This was retrospective study of patients undergoing preoperative adjuvant radiotherapy for the primary rectal tumour, followed by liver resection and finally, resection of the primary tumour. Short-term surgical outcome, overall survival (OS) and recurrence-free survival (RFS) are reported...
February 9, 2017: Colorectal Disease: the Official Journal of the Association of Coloproctology of Great Britain and Ireland
https://www.readbyqxmd.com/read/28174385/-long-term-complete-response-in-postoperative-multiple-lung-and-mediastinal-lymph-node-metastases-of-esophageal-cancer-using-systemic-chemotherapy-with-dcf-treatment-a-case-report
#14
Chihiro Katsumi, Takeo Bamba, Satoru Nakagawa, Masaki Aizawa, Atsushi Matsuki, Hiroshi Yabusaki, Keiichi Homma
A 59-year-old man was diagnosed with advanced thoracic esophageal cancer.He underwent neoadjuvant chemotherapy with cisplatin(CDDP), 5-fluorouracil(5-FU)(CF)followed by transthoracic esophagectomy with three-field lymphadenectomy. Histopathological examination revealed that the tumor was poorly differentiated squamous cell carcinoma invading the adventitia with 6 regional lymph node metastases.Four months after surgery, follow-up thoracic computed tomography (CT)showed multiple lung and mediastinal lymph node metastases...
January 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133209/-a-case-of-primary-poorly-differentiated-small-cell-carcinoma-of-the-breast-in-a-patient-with-von-recklinghausen-s-disease
#15
Kazunoshin Tachibana, Noriko Abe, Sadahiko Abe, Keita Aoto, Maiko Okano, Fumi Murakami, Satoshi Kawana, Osamu Suzuki, Kazuhiro Tasaki, Tohru Ohtake, Seiichi Takenoshita
We report a case of neuroendocrine carcinoma and poorly differentiated/small cell carcinoma ofthe breast in a patient with von Recklinghausen's disease. The patient was a 46-year-old woman who was diagnosed with von Recklinghausen's disease when she was 22 years old. She presented with left breast pain, and physical examination revealed a firm mass in the left breast. A core needle biopsy of the tumor revealed triple negative breast cancer with neuroendocrine features. We performed a simple mastectomy with lymph node dissection...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28129775/cmtm1_v17-is-associated-with-chemotherapy-resistance-and-poor-prognosis-in-non-small-cell-lung-cancer
#16
Jiahui Si, Panpan Zhang, Dan Tian, Xing Wang, Yuanyuan Ma, Jianzhi Zhang, Lu Wang, Yue Yang
BACKGROUND: Considering neoadjuvant chemotherapy (NAC) prior to surgery could shrink and reduce the primary tumor and distant micro-metastases to reduce the high relapses rates, NAC has been an accepted therapeutic management for patients with non-small cell lung cancer (NSCLC). CMTM1_v17 is highly expressed in human testis tissues and solid tumor tissues but relatively low expression was obtained in the corresponding normal tissues. This study aims to investigate the significance of CMTM1_v17 in NSCLC and its association with platinum-based NAC efficacy...
January 28, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28126333/first-line-ceritinib-versus-platinum-based-chemotherapy-in-advanced-alk-rearranged-non-small-cell-lung-cancer-ascend-4-a-randomised-open-label-phase-3-study
#17
Jean-Charles Soria, Daniel S W Tan, Rita Chiari, Yi-Long Wu, Luis Paz-Ares, Juergen Wolf, Sarayut L Geater, Sergey Orlov, Diego Cortinovis, Chong-Jen Yu, Maximillian Hochmair, Alexis B Cortot, Chun-Ming Tsai, Denis Moro-Sibilot, Rosario G Campelo, Tracey McCulloch, Paramita Sen, Margaret Dugan, Serafino Pantano, Fabrice Branle, Cristian Massacesi, Gilberto de Castro
BACKGROUND: The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known. We assessed the efficacy and safety of ceritinib versus platinum-based chemotherapy in these patients. METHODS: This randomised, open-label, phase 3 study in untreated patients with stage IIIB/IV ALK-rearranged non-squamous NSCLC was done in 134 centres across 28 countries. Eligible patients were assigned via interactive response technology to oral ceritinib 750 mg/day or platinum-based chemotherapy ([cisplatin 75 mg/m(2) or carboplatin AUC 5-6 plus pemetrexed 500 mg/m(2)] every 3 weeks for four cycles followed by maintenance pemetrexed); randomisation was stratified by World Health Organization performance status (0 vs 1-2), previous neoadjuvant or adjuvant chemotherapy, and presence of brain metastases as per investigator's assessment at screening...
March 4, 2017: Lancet
https://www.readbyqxmd.com/read/28104952/pitfalls-in-interpretation-of-fdg-pet-ct-septic-pulmonary-emboli-mimicking-metastases-in-a-case-of-gastric-carcinoma
#18
Harkirat Singh, Aftab Alam, T V S V G K Tilak, Prateek Kinra, Brijesh K Soni
Inflammatory lesions may sometimes show intense tracer uptake and mimic neoplastic lesions on (18) F-fluoro-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT). We report one such false positive case on FDG PET/CT, where septic pulmonary emboli (SPE) mimicked pulmonary metastases. A 45-year-old man with stomach cancer had an indwelling central venous catheter (CVC) in situ while on neoadjuvant chemotherapy. He underwent FDG PET/CT scan for response assessment and the images revealed multiple, intensely FDG avid, peripheral, lung nodules with feeding vessels, which were suspicious for pulmonary metastases...
October 2016: Indian Journal of Radiology & Imaging
https://www.readbyqxmd.com/read/28102506/a-comparison-of-flt-to-fdg-pet-ct-in-the-early-assessment-of-chemotherapy-response-in-stages-ib-iiia-resectable-nsclc
#19
John P Crandall, Abdel K Tahari, Rosalyn A Juergens, Julie R Brahmer, Charles M Rudin, Giuseppe Esposito, Deepa S Subramaniam, Michael V Knopp, Nathan C Hall, Prateek Gajwani, Jeffrey P Leal, Martin A Lodge, Joo H O, Edward W Gabrielson, Lalitha K Shankar, Richard L Wahl
BACKGROUND: The aim of this study was to compare the percentage change in (18)F-fluorothymidine (FLT) standard uptake value (SUV) between baseline and after one cycle of chemotherapy in patients categorized by RECIST 1.1 computed tomography (CT) as responders or non-responders after two cycles of therapy. Change in (18)F-fluorodeoxyglucose (FDG) uptake was also compared between these time points. Nine patients with newly diagnosed, operable, non-small cell lung cancer (NSCLC) were imaged with FDG positron emission tomography/CT (PET), FLT PET/CT, and CT at baseline, following one cycle of neoadjuvant therapy (75 mg/m(2) docetaxel + 75 mg/m(2) cisplatin), and again after the second cycle of therapy...
December 2017: EJNMMI Research
https://www.readbyqxmd.com/read/28049169/management-of-stage-i-and-ii-nonsmall-cell-lung-cancer
#20
Fiona McDonald, Michèle De Waele, Lizza E L Hendriks, Corinne Faivre-Finn, Anne-Marie C Dingemans, Paul E Van Schil
The incidence of stage I and II nonsmall cell lung cancer is likely to increase with the ageing population and introduction of screening for high-risk individuals. Optimal management requires multidisciplinary collaboration. Local treatments include surgery and radiotherapy and these are currently combined with (neo)adjuvant chemotherapy in specific cases to improve long-term outcome. Targeted therapies and immunotherapy may also become important therapeutic modalities in this patient group. For resectable disease in patients with low cardiopulmonary risk, complete surgical resection with lobectomy remains the gold standard...
January 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
keyword
keyword
52838
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"